Compare Fresenius Kabi Onco. with AANJANEYA LIFECARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs DR. DATSONS LABS - Comparison Results

FRESENIUS KABI ONCO.     Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. DR. DATSONS LABS FRESENIUS KABI ONCO./
DR. DATSONS LABS
 
P/E (TTM) x 22.1 -10.9 - View Chart
P/BV x 3.1 0.2 1,917.3% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 FRESENIUS KABI ONCO.   DR. DATSONS LABS
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
DR. DATSONS LABS
Mar-14
FRESENIUS KABI ONCO./
DR. DATSONS LABS
5-Yr Chart
Click to enlarge
High Rs176126 140.1%   
Low Rs7931 254.0%   
Sales per share (Unadj.) Rs37.7133.0 28.3%  
Earnings per share (Unadj.) Rs5.10.2 3,359.4%  
Cash flow per share (Unadj.) Rs6.76.6 101.7%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs42.5128.8 33.0%  
Shares outstanding (eoy) m158.2331.66 499.8%   
Bonus/Rights/Conversions -FCCB-  
Price / Sales ratio x3.40.6 573.9%   
Avg P/E ratio x25.0516.1 4.8%  
P/CF ratio (eoy) x18.911.8 159.8%  
Price / Book Value ratio x3.00.6 492.3%  
Dividend payout %00-   
Avg Mkt Cap Rs m20,1352,477 812.7%   
No. of employees `0001.2NA-   
Total wages/salary Rs m70356 1,255.7%   
Avg. sales/employee Rs Th5,176.2NM-  
Avg. wages/employee Rs Th610.4NM-  
Avg. net profit/employee Rs Th699.6NM-  
INCOME DATA
Net Sales Rs m5,9634,211 141.6%  
Other income Rs m1879 22.9%   
Total revenues Rs m5,9814,289 139.4%   
Gross profit Rs m1,430569 251.5%  
Depreciation Rs m258204 126.2%   
Interest Rs m-26430 -6.0%   
Profit before tax Rs m1,21613 9,576.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m3426 5,609.8%   
Profit after tax Rs m8065 16,789.6%  
Gross profit margin %24.013.5 177.6%  
Effective tax rate %28.148.0 58.6%   
Net profit margin %13.50.1 11,855.2%  
BALANCE SHEET DATA
Current assets Rs m5,1026,852 74.5%   
Current liabilities Rs m2,3856,711 35.5%   
Net working cap to sales %45.63.3 1,360.2%  
Current ratio x2.11.0 209.5%  
Inventory Days Days150161 93.3%  
Debtors Days Days113318 35.6%  
Net fixed assets Rs m5,1483,673 140.2%   
Share capital Rs m158317 50.0%   
"Free" reserves Rs m6,5563,761 174.3%   
Net worth Rs m6,7324,078 165.1%   
Long term debt Rs m9521,671 57.0%   
Total assets Rs m10,38812,633 82.2%  
Interest coverage x-45.81.0 -4,446.4%   
Debt to equity ratio x0.10.4 34.5%  
Sales to assets ratio x0.60.3 172.2%   
Return on assets %7.53.4 218.0%  
Return on equity %12.00.1 10,169.6%  
Return on capital %14.67.7 190.3%  
Exports to sales %74.522.9 325.3%   
Imports to sales %24.814.3 173.3%   
Exports (fob) Rs m4,441964 460.6%   
Imports (cif) Rs m1,477602 245.5%   
Fx inflow Rs m5,298964 549.5%   
Fx outflow Rs m1,772607 291.9%   
Net fx Rs m3,525357 987.8%   
CASH FLOW
From Operations Rs m1,2741,345 94.7%  
From Investments Rs m-1,204-2,256 53.4%  
From Financial Activity Rs m-196-1,200 16.3%  
Net Cashflow Rs m-126-2,111 6.0%  

Share Holding

Indian Promoters % 0.0 4.5 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 0.0 -  
FIIs % 9.6 1.4 711.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 94.1 9.7%  
Shareholders   42,599 20,807 204.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   UNICHEM LAB  AUROBINDO PHARMA  IPCA LABS  GLENMARK PHARMA  VENUS REMEDIES  

Compare FRESENIUS KABI ONCO. With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 334 Points Lower; IT and Telecom Stocks Witness Huge Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their day deep in the red. At the closing bell, the BSE Sensex stood lower by 334 points (down 0.9%).

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. - J.B.CHEMICALS COMPARISON

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS